Age Reversal Clinical Trials to Watch in 2026

Why Are Age Reversal Clinical Trials Important?

For decades, aging was considered an inevitable biological process that medicine could only manage through treatment of individual age-related diseases. This paradigm is shifting. A growing number of clinical trials are now testing interventions that target fundamental aging mechanisms, with the goal of slowing, halting, or even reversing aspects of biological aging.

These trials represent a critical step in translating laboratory discoveries into potential therapies. While animal studies have demonstrated remarkable possibilities — from partial epigenetic reprogramming to senescent cell clearance — only rigorous human clinical trials can determine whether these approaches are safe and effective for people.

The year 2026 marks an important moment in this field, with multiple trials reaching key milestones and new trials launching to test next-generation approaches.

How Clinical Trials Work: A Quick Primer

Understanding clinical trial phases helps contextualize the research discussed in this article:

Most aging-related trials in 2026 are in Phase 1 or Phase 2, reflecting the early stage of the field.

The Landmark TAME Trial

What Is TAME?

The Targeting Aging with Metformin (TAME) trial is arguably the most significant aging clinical trial in history. Led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, TAME is testing whether metformin — a widely used, inexpensive diabetes medication — can delay the onset of age-related diseases in older adults who do not have diabetes (PMID: 31451613).

Why TAME Matters

TAME’s significance extends beyond metformin itself. The trial is designed to establish a regulatory framework for treating aging as a medical condition. If TAME demonstrates that a single intervention can delay multiple age-related diseases simultaneously, it could pave the way for the FDA to recognize aging as a treatable condition — opening the door for other aging-targeted therapies.

Current Status

TAME has faced funding challenges and delays since its initial proposal, but as of 2026, enrollment is underway at multiple sites across the United States. The trial aims to enroll approximately 3,000 participants aged 65-79 and follow them for several years, monitoring the onset of age-related conditions including cardiovascular disease, cancer, cognitive decline, and mortality.

The Metformin Evidence Base

The rationale for TAME draws on decades of observational data suggesting that metformin users may experience lower rates of age-related diseases and mortality compared to non-diabetic controls. Proposed mechanisms include:

• Activation of AMPK, a key cellular energy sensor
• Reduction of mTOR signaling, which has been linked to aging in multiple organisms
• Anti-inflammatory effects through reduction of NF-kB signaling
• Improved mitochondrial function
• Potential senolytic or senomorphic effects

Senolytic Clinical Trials

Dasatinib + Quercetin (D+Q)

The combination of dasatinib (a cancer drug) and quercetin (a plant flavonoid) was the first senolytic regimen demonstrated to clear senescent cells in human patients. A preliminary clinical trial published in 2019 showed that D+Q reduced senescent cell markers in patients with diabetic kidney disease (PMID: 31542391).

Active trials in 2026:

• Phase 2 trials for idiopathic pulmonary fibrosis
• Phase 2 trials for osteoarthritis
• Phase 1/2 trials for frailty in older adults
• Pilot studies examining effects on biological age markers

Fisetin Trials

Fisetin, a naturally occurring flavonoid found in strawberries and other fruits, has shown senolytic properties in preclinical studies. Several clinical trials are investigating its potential:

• AFFIRM trial: Testing fisetin in older adults with frailty
• COVID-19 recovery: Studies examining fisetin’s potential to clear virus-induced senescent cells
• Osteoarthritis: Phase 2 trials evaluating fisetin for joint health

Unity Biotechnology’s UBX Programs

Unity Biotechnology has been developing targeted senolytic therapies for specific tissues. Their programs include:

• UBX1325: An eye-specific senolytic for age-related macular degeneration
• Pipeline programs: Senolytic approaches targeting other specific tissues

NAD+ Precursor Trials

NMN (Nicotinamide Mononucleotide)

Multiple clinical trials are evaluating NMN supplementation for its effects on aging biomarkers:

A 2022 randomized, double-blind, placebo-controlled trial demonstrated that NMN supplementation increased NAD+ levels and improved certain metabolic parameters in healthy middle-aged adults (PMID: 35927255).

Ongoing and recent trials:

NR (Nicotinamide Riboside)

Nicotinamide riboside, another NAD+ precursor, has been the subject of numerous clinical trials:

• Chromadex/Niagen trials: Multiple studies examining NR’s effects on NAD+ levels, metabolic health, and cognitive function
• NASH trial: Evaluating NR for non-alcoholic steatohepatitis
• Parkinson’s disease: Phase 2 trial examining NR as an adjunct therapy

Rapamycin and Rapalogs

Rapamycin, an mTOR inhibitor originally developed as an immunosuppressant, has emerged as one of the most promising longevity compounds based on animal studies. Research has shown that rapamycin extends lifespan in multiple organisms, including mice (PMID: 31272883).

Current Clinical Investigations

• PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity): A citizen science trial testing low-dose rapamycin in healthy middle-aged adults
• Dog Aging Project: The TRIAD study is testing rapamycin in companion dogs, which may provide translational data relevant to humans
• Everolimus trials: A rapamycin analog has been tested for its effects on immune function in older adults, with results suggesting it may improve influenza vaccine response

Key Questions for Rapamycin Trials

The primary challenges for rapamycin clinical development include:

• Dosing: The immunosuppressive doses used in transplant medicine are much higher than those proposed for longevity. Determining the optimal low-dose regimen is critical.
• Intermittent dosing: Animal studies suggest intermittent rapamycin dosing may provide longevity benefits while minimizing side effects
• Biomarkers: Identifying appropriate endpoints for aging trials, since waiting for disease outcomes requires very long follow-up periods

Mitochondrial Health Trials

Urolithin A (Mitopure)

Urolithin A, a metabolite produced by gut bacteria from ellagitannins found in pomegranates and berries, has shown promise for improving mitochondrial health through stimulation of mitophagy. A 2022 clinical trial demonstrated that urolithin A supplementation improved muscle strength, exercise performance, and biomarkers of mitochondrial health in middle-aged adults (PMID: 35596676).

Current trials:

• Phase 3 trial for muscle function in older adults
• Phase 2 trial examining effects on inflammatory biomarkers
• Studies evaluating effects on biological age measures

MitoQ and Related Compounds

Mitochondrial-targeted antioxidants are being evaluated in several clinical settings:

• MitoQ for vascular function in older adults
• SS-31 (Elamipretide) for mitochondrial myopathy and heart failure
• CoQ10 supplementation studies for various age-related conditions

Plasma Exchange and Blood Factor Trials

Building on parabiosis research, several clinical trials are exploring blood-based interventions:

Therapeutic Plasma Exchange (TPE)

Following the Conboy Lab’s 2020 findings that simple plasma dilution can rejuvenate aged tissues in mice, clinical trials are investigating whether therapeutic plasma exchange — already an FDA-approved procedure for other conditions — may have aging-related benefits.

Young Plasma Fractions

Alkahest (now part of Grifols) has conducted trials using specific fractions of young donor plasma:

• GRF6019: A young plasma fraction tested in Alzheimer’s disease patients, with preliminary results suggesting possible improvements in functional measures
• GRF6021: Being evaluated for Parkinson’s disease

Epigenetic Reprogramming: The Frontier

Where Are Human Reprogramming Trials?

As of 2026, direct in vivo epigenetic reprogramming has not yet entered human clinical trials. However, several preclinical programs are advancing toward clinical development:

• Altos Labs: The well-funded biotech is conducting extensive preclinical research on reprogramming approaches, with clinical applications potentially years away
• Shift Bioscience: Developing reprogramming-based therapies with a focus on specific age-related conditions
• Turn Biotechnologies: Working on mRNA-based delivery of reprogramming factors for ex vivo tissue rejuvenation

Gene Therapy Approaches

Several gene therapy programs tangentially related to aging are in clinical trials:

• Telomerase gene therapy: Preliminary studies have explored telomerase (TERT) gene delivery, though this remains controversial
• Klotho gene therapy: Preclinical studies are advancing toward clinical testing
• Follistatin gene therapy: Tested in small human studies for muscle wasting

Emerging Trial Areas

GLP-1 Agonists and Aging

Originally developed for diabetes and obesity, GLP-1 receptor agonists (such as semaglutide) are being investigated for potential aging-related benefits:

• Cardiovascular disease risk reduction
• Potential neuroprotective effects
• Effects on inflammatory markers
• Impact on biological age measures

Spermidine Supplementation

The natural polyamine spermidine, which induces autophagy, is being studied in several clinical trials:

• Memory enhancement in older adults
• Cardiovascular health parameters
• Cognitive decline prevention

Senomodulators

Rather than killing senescent cells, senomodulators aim to suppress the harmful SASP secreted by senescent cells while keeping the cells intact. This approach may avoid potential negative effects of completely removing senescent cells, which may serve some beneficial functions.

How to Evaluate Age Reversal Trials

When assessing clinical trials in the aging space, several factors deserve consideration:

Study Design Quality

• Randomized, double-blind, placebo-controlled: The gold standard for clinical evidence
• Sample size: Larger studies provide more reliable results
• Duration: Aging outcomes typically require long follow-up periods
• Appropriate endpoints: Biological age markers, functional measures, or disease incidence

Biomarker Endpoints

Many aging trials use surrogate endpoints rather than waiting for disease outcomes:

Red Flags

Be cautious of:

• Trials run by companies with financial conflicts of interest and no independent oversight
• Very small sample sizes (under 20 participants)
• Open-label designs without placebo controls
• Exclusive reliance on self-reported outcomes
• Clinics offering “anti-aging treatments” outside of registered clinical trials

What Does This Mean for Individuals?

While it is not advisable for individuals to self-experiment with unproven interventions, the current clinical trial landscape offers several takeaways:

1. The field is legitimate: Major research institutions and well-funded companies are conducting rigorous trials, lending credibility to the idea that aging may be modifiable
2. Multiple approaches are advancing: Rather than relying on a single strategy, the field is pursuing diverse approaches that may eventually complement each other
3. Participation is possible: Many trials are actively recruiting participants, and interested individuals can search ClinicalTrials.gov for opportunities
4. Patience is warranted: Even optimistic timelines suggest that validated aging therapies are likely several years away from clinical availability
5. Lifestyle interventions remain foundational: While waiting for pharmaceutical breakthroughs, evidence-based lifestyle practices — exercise, nutrition, sleep, stress management — continue to offer the best-supported approach to healthy aging

Looking Ahead: What to Expect in 2027 and Beyond

The next several years may bring significant developments in age reversal clinical research:

• TAME results: Initial data from the TAME trial could reshape how regulators view aging as a medical target
• Senolytic approvals: If Phase 2 senolytic trials show positive results, Phase 3 trials could begin for specific age-related conditions
• Reprogramming milestones: The first human safety studies of partial reprogramming approaches may begin
• Biomarker validation: Improved biological age measures could accelerate trial design and reduce the time needed to evaluate aging interventions
• Combination approaches: Trials testing multiple interventions together may begin to appear

The clinical trial landscape for age reversal in 2026 represents an unprecedented convergence of scientific understanding, technological capability, and financial investment. While transformative therapies may still be years away, the breadth and rigor of current research efforts suggest that meaningful progress toward modifying the aging process is increasingly within reach.